Figure 3.

AZD0530 treatment attenuates CBF recovery in EC-targeted miR-15a/16-1 cKO mice at prolonged reperfusion timepoints after cerebral ischemia. EC-miR-15a/16-1 cKO mice and WT littermate controls were subjected to 1 h MCAO followed by 28d reperfusion. Vehicle (Veh) or AZD0530 (AZD, 20 mg/kg) was administered daily to both genotypes at 3-21d after MCAO by oral gavage. (a–b) Representative CBF images (a) are shown at 3 d, 7 d, 14 d, 21 d and 28 d after the onset of reperfusion. Two identical elliptical ROIs were selected as indicated on the ipsilateral and contralateral hemispheres. The relative CBF was first determined as the ratio of ischemic to non-ischemic values, and then normalized to the pre-MCAO baseline for each animal. Quantitative data analysis (b) demonstrated that the relative CBF value in EC-miR-15a/16-1 cKO mice exhibited a significant increase at 14 d, 21 d and 28 d of reperfusion after MCAO under vehicle treatment. AZD0530 treatment significantly attenuated the increased CBF in EC-miR-15a/16-1 cKO mice at 21 d and 28 d reperfusion. No significant difference was found between WT + Veh and WT + AZD groups at any time point after MCAO. Data are expressed as the mean ± SD. n = 6-7 for each group. *p < 0.05, **p < 0.01, ***p < 0.001 as indicated. Statistical analysis was performed by one-way ANOVA followed by Bonferroni's multiple comparison tests.